Heron Therapeutics Inc (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced that data from Heron’s recently completed MAGIC Study of SUSTOL® (granisetron) Injection, extended release, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC), will be presented at the American Society of Clinical Oncology (ASCO) 2015 Breast Cancer Symposium on Saturday, September 26, 2015 in San Francisco, CA.
Heron will present a poster and give an oral presentation for the abstract titled “Phase III Study of APF530 versus Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial.” (Original Source)
Shares of Heron Therapeutics closed yesterday at $34.67 HRTX has a 1-year high of $42.24 and a 1-year low of $6.51. The stock’s 50-day moving average is $34.56 and its 200-day moving average is $24.45.
On the ratings front, Heron has been the subject of a number of recent research reports. In a report issued on August 17, Cowen analyst Boris Peaker reiterated a Buy rating on HRTX, with a price target of $47, which represents a potential upside of 35.6% from where the stock is currently trading. Separately, on August 7, Brean Murray Carret’s Jonathan Aschoff reiterated a Buy rating on the stock and has a price target of $45.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Boris Peaker and Jonathan Aschoff have a total average return of 26.6% and 7.2% respectively. Peaker has a success rate of 51.5% and is ranked #65 out of 3768 analysts, while Aschoff has a success rate of 47.2% and is ranked #391.
Heron Therapeutics Incis a biotechnology company, developing products to address unmet medical needs. ItsproprietaryBiochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.